Tvardi Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TVRD research report →
Companytvarditherapeutics.com BioSpace +4
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
- CEO
- Imran Alibhai
- IPO
- 2025
- Employees
- 17
- HQ
- Sugar Land, TX, US
Price Chart
Valuation
- Market Cap
- $36.12M
- P/E
- -2.34
- P/S
- 0.00
- P/B
- 2.49
- EV/EBITDA
- -0.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -64.17%
- ROIC
- -200.59%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-18,214,000 · 74.30%
- EPS
- $-2.46 · 94.72%
- Op Income
- $-26,748,000
- FCF YoY
- 62.08%
Performance & Tape
- 52W High
- $43.65
- 52W Low
- $2.75
- 50D MA
- $3.43
- 200D MA
- $10.89
- Beta
- 0.30
- Avg Volume
- 47.59K
Get TickerSpark's AI analysis on TVRD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 29, 26 | O'Brien Stephen Paul | other | 15,000 |
| Jan 29, 26 | Conn Avi Daniel | other | 45,000 |
| Jan 29, 26 | Kauh John Saewook M.D. | other | 45,000 |
| Jan 29, 26 | Alibhai Imran Nizamudin | other | 115,000 |
| Dec 16, 25 | O'Brien Stephen Paul | other | 4,000 |
| Dec 16, 25 | Kauh John Saewook M.D. | other | 17,500 |
| Dec 16, 25 | Conn Avi Daniel | other | 17,500 |
| Dec 16, 25 | Alibhai Imran Nizamudin | other | 47,500 |
| Jul 7, 25 | Tweardy Samuel David | other | 315,658 |
| Apr 15, 25 | HALL WALLACE L JR | other | 202,044 |
Our TVRD Coverage
We haven't published any research on TVRD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TVRD Report →